Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Korean J Radiol. 2021 Dec;22(12):1938-1945. doi: 10.3348/kjr.2021.0350. Epub 2021 Oct 26.
Breast radiologists are increasingly seeing patients with axillary adenopathy related to COVID-19 vaccination. Vaccination can cause levels I-III axillary as well as cervical lymphadenopathy. Appropriate management of vaccine-related adenopathy may vary depending on clinical context. In patients with current or past history of malignancy, vaccine-related adenopathy can be indistinguishable from nodal metastasis. This article presents imaging findings of oncology patients with adenopathy seen in the axilla or neck on cross-sectional imaging (breast MRI, CT, or PET-CT) after COVID-19 vaccination. Management approach and rationale is discussed, along with consideration on strategies to minimize false positives in vaccinated cancer patients. Time interval between vaccination and adenopathy seen on breast MRI, CT, or PET-CT is also reported.
乳腺放射科医生越来越多地发现与 COVID-19 疫苗接种相关的腋窝淋巴结病患者。疫苗接种可引起 I-III 级腋窝和颈部淋巴结病。疫苗相关淋巴结病的适当处理可能取决于临床情况。在当前或既往有恶性肿瘤病史的患者中，疫苗相关淋巴结病与淋巴结转移可能难以区分。本文介绍了 COVID-19 疫苗接种后在乳腺 MRI、CT 或 PET-CT 上发现的腋窝或颈部淋巴结病的癌症患者的影像学表现。讨论了管理方法和原理，并考虑了减少接种癌症患者假阳性的策略。还报告了疫苗接种与乳腺 MRI、CT 或 PET-CT 上发现的淋巴结病之间的时间间隔。
